SGLT2 is a well-known member in the kidney for glucose reabsorption from urine, and SGLT2 inhibitors are effective medicines in the treatment of type 2 diabetes for promotion of glucose discharge in urine. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.